GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DA) » Definitions » Other Net Income (Loss)

Melodiol Global Health (ASX:ME1DA) Other Net Income (Loss) : A$-16.93 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health Other Net Income (Loss)?

Melodiol Global Health's Other Net Income (Loss) for the six months ended in Dec. 2023 was A$-16.93 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-16.93 Mil.

Melodiol Global Health's quarterly Other Net Income (Loss) stayed the same from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil) but then declined from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$-16.93 Mil).

Melodiol Global Health's annual Other Net Income (Loss) increased from Dec. 2021 (A$0.00 Mil) to Dec. 2022 (A$0.00 Mil) but then declined from Dec. 2022 (A$0.00 Mil) to Dec. 2023 (A$-16.93 Mil).


Melodiol Global Health Other Net Income (Loss) Historical Data

The historical data trend for Melodiol Global Health's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Other Net Income (Loss) Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial - - - - -16.93

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -16.93

Melodiol Global Health Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-16.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (ASX:ME1DA) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DA) Headlines

No Headlines